Randomized trial finds hypofractionated whole-breast radiation with concurrent boost comparable to six weeks of treatment for patients with higher-risk disease
/PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients.